Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2182 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Ersilia M. DeFilippis¹, Denis Wahl² and Stephane Zuily², ¹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France
Background/Purpose : Livedo reticularis (LR) is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our…
Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Cécile Yelnik^1,2, Flint Porter^3,4, Ware D. Branch^3,4, Jill P. Buyon⁵, Marta Guerra⁶, Carl Laskin⁷, Michael Lockshin⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Lisa R. Sammaritano¹¹, Mary D. Stephenson¹², Mimi Y. Kim¹³ and Jane E. Salmon^11,14, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³University of Utah, Salt Lake City, UT, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²University of Illinois College of Medicine, Chicago, IL, ¹³Albert Einstein College of Medicine, Bronx, NY, ¹⁴Hospital for Special Surgery, New York, NY
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…
Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Savino Sciascia¹, Beverely J Hunt², Eva Talavera-Garcia³, Gloria Lliso³, Munther Khamashta³ and Mª Jose Cuadrado⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ³Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
Abstract Number: 2187 • 2015 ACR/ARHP Annual Meeting
Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus² and W. David Branch³, ¹Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: Infertility is a common condition, affecting 8-12% of couples in childbearing age. Even though the association of aPL with infertility is highly debated, infertile…
Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
YU PEI CHOCK¹, DENIS WAHL² and STEPHANE ZUILY³, ¹KENT MEMORIAL HOSPITAL, WARWICK, RI, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…
Abstract Number: 2193 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Hemolytic Anemia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
OZAN UNLU¹, DENIS WAHL^2,3 and STEPHANE ZUILY^3,4, ¹Rheumatology Department, Barbara Volcker Center for Women and Rheumatic Disease, New York, NY, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ³Inserm, UMR_S 1116, Nancy, France, ⁴CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Title: Increased Risk of Hemolytic Anemia Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.Background/Purpose : Hemolytic anemia (HA)…
Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Eulalia Armengol¹, Gloria Albert¹, Alex Roset³, Patricia Siguenza³, Xavier Juanola⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…
Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting
Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Alessandra Zanola¹, Laura Andreoli¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Research, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…
Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Mileka Gilbert¹ and Lenore M. Buckley², ¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ²Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…
Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Laura Andreoli¹, Alessandra Zanola¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²9900 Old Grove road, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…
Abstract Number: 2 • 2014 ACR/ARHP Annual Meeting
Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Ikuma Nakagawa¹, Kenji Oku², Olga Amengual¹, Ryo Hisada¹, Eri Sugawara¹, Kazumasa Ohmura¹, Tomoko Fukui¹, Sanae Shimamura¹, Haruki Shida¹, Toshiyuki Watanabe¹, Yuka Shimizu¹, Michihito Kono¹, Takashi Kurita¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated syndrome refers to organ dysfunctions developed in the existence of antiphospholipid antibodies (aPL), apart from the typical manifestations of antiphospholipid syndrome (APS) such…
Abstract Number: 2864 • 2014 ACR/ARHP Annual Meeting
Markers of Thrombotic Events in Autoimmune Diseases:Comparison of Antiphospholipid Score (aPL-S) and Global Anti-Phospholipid Syndrome Score (GAPSS)
Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose Recently, new scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) have been proposed in sequence: the Antiphospholipid Score(aPL-S) and…
Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting
External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß₂-Glycoprotein I. a Prospective Multicentre Cohort Study
Stephane Zuily¹, Bas De Laat², Veronique Regnault³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Zakera Shums⁶, Roger Albesa⁷, Gary L Norman⁶, Philip de Groot⁸, Anne-Christine Rat⁹, Jacques Ninet¹⁰, Nadine Magy-Bertrand¹¹, Jean-Louis Pasquali¹², Marc Lambert¹³, Bernard Lorcerie¹⁴, Thomas Lecompte¹⁵, Francis Guillemin¹⁶ and Denis Wahl¹⁷, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, CHU Nancy, Vandoeuvre, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶INOVA Diagnostics, San Diego, CA, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, ¹⁰Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹¹Bensançon University Hospital, Besançon, France, ¹²Service de Medecine Interne, Nouvel Hospital Civil, Strasbourg Cedex, France, ¹³Lille University Hospital, Lille, France, ¹⁴Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁵Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁶INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ¹⁷Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…
Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome
Srilakshmi Yalavarthi¹, Levi F. Mazza¹, Alexandra E. Morris¹, Carlos Núñez-Álvarez², Diego Hernández², Paula L. Bockenstedt³, Antonio R. Cabral⁴ and Jason S. Knight¹, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose: Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications. However, the interaction of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].